Premium
Duvelisib, an oral dual PI3K‐δ,γ inhibitor, efficacy and safety in patients with relapsed or refractory (RR) peripheral T‐cell lymphoma: rationale for the phase 2 PRIMO trial
Author(s) -
Horwitz S.M.,
Foss F.M.,
Porcu P.,
Moskowitz A.,
MehtaShah N.,
Jacobsen E.,
Khodadoust M.S.,
Kim Y.H.,
Weinstock D.,
Lustgarten S.,
Baglio M.,
Youssoufian H.,
Brammer J.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.33_2629
Subject(s) - medicine , lymphoma , romidepsin , regimen , oncology , refractory (planetary science) , phases of clinical research , peripheral t cell lymphoma , follicular lymphoma , gastroenterology , clinical trial , pharmacology , immunology , t cell , immune system , chemistry , physics , histone deacetylase , biochemistry , astrobiology , gene , histone
pts, particularly in those with tumors of AITL histology and high CXCL12 expression and enrollment in the CXCL12+ cohort continues.